ExploreWatchlistsPricing
  1. JP-listed companies
  2. Momotaro-Gene Inc.
  3. Financials
  4. Total assets

Momotaro-Gene Inc. (E33052)

Market cap
P/E ratio
Momotaro Genen develops innovative gene therapy drugs using the REIC cancer suppressor gene discovered at Okayama University to selectively kill cancer cells.
SummaryFinancialsDividendsHistoryWorkforce
Period EndTotal assets (Million JPY)YoY (%)
Mar 31, 202385-7.13%
Mar 31, 202292-74.62%
Mar 31, 2021362-46.02%
Mar 31, 2020671-31.60%
Mar 31, 2019981+16.50%
Mar 31, 2018842-14.54%
Mar 31, 2017985+351.23%
Mar 31, 2016218+373.57%
Mar 31, 201546+482.94%
Mar 31, 20148-41.80%
Mar 31, 201314-47.46%
Mar 31, 201226+4.51%
Mar 31, 201125-20.93%
Mar 31, 201031-70.74%
Mar 31, 2009107

Income Statement

RevenueRevenue growth (%)Cost of revenueGross profitGross margin (%)Research & developmentSelling, general & administrativeOperating margin (%)Operating expenses Operating income Income before tax Pretax margin (%)Provision for income taxesEffective tax rate (%)Net income Net income margin (%)Earnings per shareDiluted EPSDividend payout ratio (%)Dividend per shareEBITDAEBITDA margin (%)

Balance Sheet

Cash and cash equivalents Marketable securities, current Total cash & short-term investmentsAccounts receivable, netInventoriesTotal current assetsProperty, plant and equipment, netMarketable securities, non-current Total non-current assetsTotal assets Accounts payableShort-term debtLong-term debt, current Total current liabilitiesLong-term debt, non-current Total non-current liabilitiesTotal liabilities Common stock and paid-in capital Retained earningsStockholders' equityTotal debtNet debtD/E ratio (%)Working capital

Cash Flow

Depreciation & amortizationStock-based compensationCash from operations Capital expendituresCash from investing Payments for dividends Repurchases of common stockProceeds from issuance of term debt, netRepayments of term debtCash from financing Free cash flowFCF margin (%)
AI Chat